Thursday, May 29, 2014
Publication and contact
Human embryonic stem cells
(hESCs) generated from somatic cell nuclear transfer (SCNT) using postnatal
SCNT could be useful for
creating patient-matched hESCs for disease modeling and therapeutic
applications. Previous efforts to reliably generate hESCs with nuclear
transfer protocols have been limited to using nuclei from fetal as opposed to
postnatal somatic cells. Fibroblasts from a 32-year-old female with type 1
diabetes or a newborn male were fused to enucleated donor human oocytes and
activated with an oocyte activation protocol. A subset of the oocytes bearing
the diploid genome of the donor fibroblasts developed into blastocysts, which
were used to establish stable hESC lines. Next steps include comparing
induced pluripotent stem (iPS) cell lines to nuclear transfer cell lines of
the same genetic makeup to understand key differences between the two types
Published online May 29, 2014
Patent application filed;
licensing status undisclosed
Yamada, M. et al. Nature;
published online April 28, 2014;
Contact: Dieter Egli, The
New York Stem Cell Foundation, New York, N.Y.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]